Other Therapies Approved for Patients With MF

Dr Anthony Hunter reviews the other three approved JAK inhibitors for treatment of myelofibrosis: ruxolitinib, fedratinib, and pacritinib.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Case Presentation: A 76-Year-Old Woman With Newly-Diagnosed Myelofibrosis (MF)

EP: 2.Defining Myelofibrosis

EP: 3.Types of Myelofibrosis

EP: 4.Treatment Goals for Patients With MF

EP: 5.When to Initiate Therapy in Patients With MF

EP: 6.Rationale for Treatment With Momelotinib in Patients With MF

EP: 7.Managing Anemia in Patients With MF Receiving Momelotinib

EP: 8.Momelotinib in MF: Data from the SIMPLIFY-1 Trial

Now Viewing

EP: 9.Other Therapies Approved for Patients With MF

EP: 10.Advice for Clinicians Treating Patients With MF

Recent Videos

Academic Perspectives on the Evolving Treatment Landscape in MPNs

Adverse Events Monitoring and Management in BPDCN Treatment

Academic Perspectives on Treatment Decisions for BPDCN

Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches

Advances in MPN Management: Insights From MANIFEST-2 and Beyond

Ongoing studies of Ra-223–based combinations

Academic Perspectives on Systemic Therapy for Advanced uHCC

Ongoing studies of Ra- 223–based combinations

Protecting bone health for patients receiving Ra-223 + ARPI combination

Optimizing Frontline TKI Therapy in Advanced uHCC: Managing Adverse Events